The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies : HIPEC Technologies
(2024) In Annals of Surgical Oncology 31(10). p.7090-7110- Abstract
This manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC. To identify the role of heat and its application forms in treating peritoneal metastases. To provide recommendations regarding the correct dosimetry of intraperitoneal chemotherapy drugs and their carrier solutions. To identify for each intraperitoneal chemotherapy regimen the best dosimetry and fractionation. To identify areas of future research pertaining to HIPEC technology and regimens. This consensus was performed by the Delphi technique and comprised two rounds of voting.... (More)
This manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC. To identify the role of heat and its application forms in treating peritoneal metastases. To provide recommendations regarding the correct dosimetry of intraperitoneal chemotherapy drugs and their carrier solutions. To identify for each intraperitoneal chemotherapy regimen the best dosimetry and fractionation. To identify areas of future research pertaining to HIPEC technology and regimens. This consensus was performed by the Delphi technique and comprised two rounds of voting. In total, 96 of 102 eligible panelists replied to both Delphi rounds (94.1%) with a consensus of 39/51 questions on HIPEC technical aspects. Among the recommendations that met with the strongest consensus were those concerning the dose of HIPEC drug established in mg/m2, a target temperature of at least 42°C, and the use of at least three temperature probes to pursue hyperthermia. Ninety minutes as the ideal HIPEC duration seemed to make consensus. These results should be considered when designing new clinical trials in patients with peritoneal surface malignancies.
(Less)
- author
- Van der Speeten, Kurt ; Kusamura, Shigeki ; Villeneuve, Laurent ; Piso, Pompiliu ; Verwaal, Vic J. LU ; González-Moreno, Santiago and Glehen, Olivier
- publishing date
- 2024-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cytoreductive Surgery, Hyperthermia, Intraperitoneal Chemotherapy, Peritoneal Metastases
- in
- Annals of Surgical Oncology
- volume
- 31
- issue
- 10
- pages
- 7090 - 7110
- publisher
- Springer
- external identifiers
-
- scopus:85199264137
- pmid:39037523
- ISSN
- 1068-9265
- DOI
- 10.1245/s10434-024-15513-4
- language
- English
- LU publication?
- no
- additional info
- Publisher Copyright: © Society of Surgical Oncology 2024.
- id
- a5d1a1ea-c893-474a-b09e-4517827bde58
- date added to LUP
- 2025-05-24 20:37:11
- date last changed
- 2025-07-06 00:11:35
@article{a5d1a1ea-c893-474a-b09e-4517827bde58, abstract = {{<p>This manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC. To identify the role of heat and its application forms in treating peritoneal metastases. To provide recommendations regarding the correct dosimetry of intraperitoneal chemotherapy drugs and their carrier solutions. To identify for each intraperitoneal chemotherapy regimen the best dosimetry and fractionation. To identify areas of future research pertaining to HIPEC technology and regimens. This consensus was performed by the Delphi technique and comprised two rounds of voting. In total, 96 of 102 eligible panelists replied to both Delphi rounds (94.1%) with a consensus of 39/51 questions on HIPEC technical aspects. Among the recommendations that met with the strongest consensus were those concerning the dose of HIPEC drug established in mg/m<sup>2</sup>, a target temperature of at least 42°C, and the use of at least three temperature probes to pursue hyperthermia. Ninety minutes as the ideal HIPEC duration seemed to make consensus. These results should be considered when designing new clinical trials in patients with peritoneal surface malignancies.</p>}}, author = {{Van der Speeten, Kurt and Kusamura, Shigeki and Villeneuve, Laurent and Piso, Pompiliu and Verwaal, Vic J. and González-Moreno, Santiago and Glehen, Olivier}}, issn = {{1068-9265}}, keywords = {{Cytoreductive Surgery; Hyperthermia; Intraperitoneal Chemotherapy; Peritoneal Metastases}}, language = {{eng}}, number = {{10}}, pages = {{7090--7110}}, publisher = {{Springer}}, series = {{Annals of Surgical Oncology}}, title = {{The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies : HIPEC Technologies}}, url = {{http://dx.doi.org/10.1245/s10434-024-15513-4}}, doi = {{10.1245/s10434-024-15513-4}}, volume = {{31}}, year = {{2024}}, }